Nanomaterials in COVID-19 Drug Development

Alaa A. A. Aljabali, Ángel Serrano-aroca, Kenneth Lundstrom, Murtaza M. Tambuwala

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Nanotechnology has proved efficient for platform innovations and nucleic acid, and therapeutics in cancer immunotherapy and vaccine development. While several regions of the world remain in lockdown, research has focused on nano-formulations of COVID-19 therapeutic agents and vaccines over recent months. Several nanotechnology research laboratories have been accessible to reroute their energies, creating vaccine or nano-formulations of COVID-19 therapeutic agents. Nanotechnology indeed presents a particular approach to answer some central questions in preclinical and clinical COVID-19 research. Thus the nanotechnology sector has sought to harness properties of viruses to imitate their actions to create virus-like nanomaterials for a long time. For example, viruses have been developed for selective drug delivery. Carbon-based nanomaterials, such as fullerene, carbon dots, graphene, and derivatives, have shown to be promising antivirals to combat COVID-19.
Original languageEnglish
Title of host publicationCOVID-19
Subtitle of host publicationFrom Bench to Bedside
PublisherCRC Press
Pages150-160
ISBN (Electronic)9781003190394
DOIs
Publication statusPublished - 7 Feb 2022

Fingerprint

Dive into the research topics of 'Nanomaterials in COVID-19 Drug Development'. Together they form a unique fingerprint.

Cite this